These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
623 related articles for article (PubMed ID: 11929334)
1. Bivalirudin: a review of its potential place in the management of acute coronary syndromes. Carswell CI; Plosker GL Drugs; 2002; 62(5):841-70. PubMed ID: 11929334 [TBL] [Abstract][Full Text] [Related]
2. Bivalirudin: a direct thrombin inhibitor. Gladwell TD Clin Ther; 2002 Jan; 24(1):38-58. PubMed ID: 11833835 [TBL] [Abstract][Full Text] [Related]
3. Bivalirudin as a replacement for unfractionated heparin in unstable angina/non-ST-elevation myocardial infarction: observations from the TIMI 8 trial. The Thrombolysis in Myocardial Infarction. Antman EM; McCabe CH; Braunwald E Am Heart J; 2002 Feb; 143(2):229-34. PubMed ID: 11835024 [TBL] [Abstract][Full Text] [Related]
4. Bivalirudin for percutaneous coronary intervention and in acute coronary syndromes. Bates ER Curr Cardiol Rep; 2001 Sep; 3(5):348-54. PubMed ID: 11504570 [TBL] [Abstract][Full Text] [Related]
5. Pharmacology and clinical use of bivalirudin. Sciulli TM; Mauro VF Ann Pharmacother; 2002 Jun; 36(6):1028-41. PubMed ID: 12022907 [TBL] [Abstract][Full Text] [Related]
6. Bivalirudin: an anticoagulant for acute coronary syndromes and coronary interventions. White HD; Chew DP Expert Opin Pharmacother; 2002 Jun; 3(6):777-88. PubMed ID: 12036417 [TBL] [Abstract][Full Text] [Related]
7. Bivalirudin, a bivalent, thrombin specific anticoagulant as an alternative to heparin in interventional procedures as an alternative to heparin in interventional procedures. Chew DP Hamostaseologie; 2002 Aug; 22(3):60-6. PubMed ID: 12215763 [TBL] [Abstract][Full Text] [Related]
8. A randomized comparison of bivalirudin and heparin in patients undergoing coronary angioplasty for postinfarction angina. Hirulog Angioplasty Study Investigators. Bittl JA; Feit F Am J Cardiol; 1998 Oct; 82(8B):43P-49P. PubMed ID: 9809891 [TBL] [Abstract][Full Text] [Related]
9. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. White H; Lancet; 2001 Dec; 358(9296):1855-63. PubMed ID: 11741625 [TBL] [Abstract][Full Text] [Related]
10. Adjunctive use of direct thrombin inhibitors in patients receiving fibrinolytic therapy for acute myocardial infarction. French JK; Edmond JJ; Gao W; White HD; Eikelboom JW Am J Cardiovasc Drugs; 2004; 4(2):107-15. PubMed ID: 15049722 [TBL] [Abstract][Full Text] [Related]
11. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators. Bittl JA; Strony J; Brinker JA; Ahmed WH; Meckel CR; Chaitman BR; Maraganore J; Deutsch E; Adelman B N Engl J Med; 1995 Sep; 333(12):764-9. PubMed ID: 7643883 [TBL] [Abstract][Full Text] [Related]
12. Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data. Direct Thrombin Inhibitor Trialists' Collaborative Group Lancet; 2002 Jan; 359(9303):294-302. PubMed ID: 11830196 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of bivalirudin versus heparins in reduction of cardiac outcomes in acute coronary syndrome and percutaneous coronary interventions. Singh S; Molnar J; Arora R J Cardiovasc Pharmacol Ther; 2007 Dec; 12(4):283-91. PubMed ID: 18172222 [TBL] [Abstract][Full Text] [Related]
14. Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: an analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial. Rajagopal V; Lincoff AM; Cohen DJ; Gurm HS; Hu T; Desmet WJ; Kleiman NS; Bittl JA; Feit F; Topol EJ Am Heart J; 2006 Jul; 152(1):149-54. PubMed ID: 16824845 [TBL] [Abstract][Full Text] [Related]
15. Direct thrombin inhibition and thrombolytic therapy: rationale for the Hirulog and Early Reperfusion/Occlusion (HERO-2) trial. White HD Am J Cardiol; 1998 Oct; 82(8B):57P-62P. PubMed ID: 9809893 [TBL] [Abstract][Full Text] [Related]
16. Bivalirudin: a review of its use in patients undergoing percutaneous coronary intervention. Moen MD; Keating GM; Wellington K Drugs; 2005; 65(13):1869-91. PubMed ID: 16114983 [TBL] [Abstract][Full Text] [Related]
17. Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale. Stone GW; Bertrand M; Colombo A; Dangas G; Farkouh ME; Feit F; Lansky AJ; Lincoff AM; Mehran R; Moses JW; Ohman M; White HD Am Heart J; 2004 Nov; 148(5):764-75. PubMed ID: 15523305 [TBL] [Abstract][Full Text] [Related]
18. Hirudin (desirudin) and Hirulog (bivalirudin) in acute ischaemic syndromes and the rationale for the Hirulog/Early Reperfusion Occlusion (HERO-2) Study. White HD; Ellis CJ; French JK; Aylward P Aust N Z J Med; 1998 Aug; 28(4):551-4. PubMed ID: 9777138 [TBL] [Abstract][Full Text] [Related]
19. Desirudin: a review of its use in the management of thrombotic disorders. Matheson AJ; Goa KL Drugs; 2000 Sep; 60(3):679-700. PubMed ID: 11030473 [TBL] [Abstract][Full Text] [Related]